Symbol="NRIX"
AssetType="Common Stock"
Name="Nurix TherapeuticsÂ Inc"
Description="Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company is headquartered in San Francisco, California."
CIK="1549595"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="1700 OWENS STREET, SUITE 205, SAN FRANCISCO, CA, US"
FiscalYearEnd="November"
LatestQuarter="2023-05-31"
MarketCapitalization="475253000"
EBITDA="-179164992"
PERatio="None"
PEGRatio="None"
BookValue="6.44"
DividendPerShare="0"
DividendYield="0"
EPS="-3.4"
RevenuePerShareTTM="0.795"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.285"
ReturnOnEquityTTM="-0.616"
RevenueTTM="41691000"
GrossProfitTTM="-145870000"
DilutedEPSTTM="-3.4"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0.318"
AnalystTargetPrice="28.92"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="14.31"
PriceToBookRatio="1.701"
EVToRevenue="6.41"
EVToEBITDA="-1.536"
Beta="1.625"
num_52WeekHigh="19.91"
num_52WeekLow="8.34"
num_50DayMovingAverage="10.18"
num_200DayMovingAverage="10.89"
SharesOutstanding="48200100"
DividendDate="None"
ExDividendDate="None"
symbol="NRIX"
open="9.84"
high="10.20"
low="9.66"
price="9.75"
volume="268869.00"
latest_trading_day="2023-07-18"
previous_close="9.86"
change="-0.11"
change_percent="-1.1156%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="41"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="59"
Volume_recent_avg="349669"
Change_recent_avg="-0.02"
Delta_recent_avg="0.65"
Variance_recent_avg="0.32"
Change_ratio_recent_avg="-0.31"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="59"
Aroon_momentum_negative="41"
image_negative_thumbnail_id_1="1098"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0131.jpeg"
image_negative_thumbnail_id_2="502"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0103.jpeg"
image_neutral_thumbnail_id_1="569"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0030.jpeg"
image_neutral_thumbnail_id_2="583"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0016.jpeg"
image_positive_thumbnail_id_1="1004"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0166.jpeg"
image_positive_thumbnail_id_2="966"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0128.jpeg"
image_professor_thumbnail_id_1="1189"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0023.jpeg"
image_professor_thumbnail_id_2="1170"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0004.jpeg"
